5NHL

Human Erk2 with an Erk1/2 inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.07 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.209 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

Ward, R.A.Bethel, P.Cook, C.Davies, E.Debreczeni, J.E.Fairley, G.Feron, L.Flemington, V.Graham, M.A.Greenwood, R.Griffin, N.Hanson, L.Hopcroft, P.Howard, T.D.Hudson, J.James, M.Jones, C.D.Jones, C.R.Lamont, S.Lewis, R.Lindsay, N.Roberts, K.Simpson, I.St-Gallay, S.Swallow, S.Tang, J.Tonge, M.Wang, Z.Zhai, B.

(2017) J. Med. Chem. 60: 3438-3450

  • DOI: 10.1021/acs.jmedchem.7b00267
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significa ...

    There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclinical models. This article reports on our recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-molecular-weight, modestly active, and highly promiscuous chemical start point, compound 4. To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was critical in the rapid exploration of this template to compound 35, which was active when tested in in vivo antitumor efficacy experiments.


    Organizational Affiliation

    IMED Oncology and Discovery Sciences, AstraZeneca , Darwin Building, and AstraZeneca, Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Mitogen-activated protein kinase 1
A
381Homo sapiensMutation(s): 0 
Gene Names: MAPK1 (ERK2, PRKM1, PRKM2)
EC: 2.7.11.24
Find proteins for P28482 (Homo sapiens)
Go to Gene View: MAPK1
Go to UniProtKB:  P28482
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
A
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
8XB
Query on 8XB

Download SDF File 
Download CCD File 
A
(6~{R})-5-(2-methoxyethyl)-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-6,7-dihydro-1~{H}-pyrrolo[3,2-c]pyridin-4-one
C20 H25 N7 O2
PNXHDOWDWLRBSB-CYBMUJFWSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
8XBIC50: <0.3 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.07 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.209 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 48.910α = 90.00
b = 71.340β = 111.05
c = 61.160γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
Aimlessdata scaling
BUSTERrefinement
xia2data reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2017-04-19
    Type: Initial release
  • Version 1.1: 2017-05-10
    Type: Database references